Ignite Creation Date:
2024-05-06 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03502876
Status:
COMPLETED
Last Update Posted:
2020-05-18
First Post:
2018-04-11
Brief Title:
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia CLL
Sponsor:
French Innovative Leukemia Organisation
Organization:
French Innovative Leukemia Organisation
Study Overview
Official Title:
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia CLL Analysis of Real-life Data Snapshot at 3 Years From the End of Ibrutinib ATU A National Study of the FILO-LLC Group
Status:
COMPLETED
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessment of the mutational profile of the residual clone and the distribution of lymphocyte subpopulations at 3 years of treatment with ibrutinib
This project has an epidemiological part to establish the percentage of patients in a real-life situation still undergoing treatment 3 years after its initiation as well as a biological part to determine the evolution of the clone and the prevalence of BTK mutations and PLCg2 in the absence of clinical or biological criteria for scalability
This project has an epidemiological part to establish the percentage of patients in a real-life situation still undergoing treatment 3 years after its initiation as well as a biological part to determine the evolution of the clone and the prevalence of BTK mutations and PLCg2 in the absence of clinical or biological criteria for scalability
Detailed Description:
Observationnal and biological study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None